PDGFRB and prostate adenocarcinoma: The top cancer-specific overexpressed targets included Bruton’s tyrosine kinase (BTK) in PRAD (overexpressed in 27% of PRAD tumors, FDR = 2.6E − 5), CDK6 in MB (24%, FDR = 1.5E − 3), platelet-derived growth factor receptor-β (PDGFRB) in HCC (22%, FDR = 7.7E − 5), and RPS6KB1 in STAD (20%, FDR = 1.7E − 4; Fig. 3d, e and Supplementary Fig. 2b).